Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?
暂无分享,去创建一个
[1] Y Li,et al. Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 A resolution. , 1995, Archives of biochemistry and biophysics.
[2] Julio Caballero,et al. Docking and quantitative structure–activity relationship studies for sulfonyl hydrazides as inhibitors of cytosolic human branched-chain amino acid aminotransferase , 2009, Molecular Diversity.
[3] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[4] Julio Caballero,et al. Investigation of the Differences in Activity between Hydroxycycloalkyl N1 Substituted Pyrazole Derivatives As Inhibitors of B-Raf Kinase by Using Docking, Molecular Dynamics, QM/MM, and Fragment-Based De Novo Design: Study of Binding Mode of Diastereomer Compounds , 2011, J. Chem. Inf. Model..
[5] Amy L. Lane,et al. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. , 2013, Journal of medicinal chemistry.
[6] David S. Goodsell,et al. A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..
[7] Richard A. Lewis,et al. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. , 2004, Journal of medicinal chemistry.
[8] Julio Caballero,et al. Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA , 2015, PloS one.
[9] Fernando D. González Nilo,et al. Insights into the Structural Basis of N2 and O6 Substituted Guanine Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors: Prediction of the Binding Modes and Potency of the inhibitors by Docking and ONIOM Calculations , 2009, J. Chem. Inf. Model..
[10] Didier Rognan,et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.
[11] G. Klebe,et al. Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.
[12] Mike Welch,et al. Potent and selective pyrazole-based inhibitors of B-Raf kinase. , 2008, Bioorganic & medicinal chemistry letters.
[13] R. Kroemer. Structure-based drug design: docking and scoring. , 2007, Current protein & peptide science.
[14] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[15] M. Mezei,et al. Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.
[16] Andrea Mattevi,et al. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] Gennady Verkhivker,et al. Deciphering common failures in molecular docking of ligand-protein complexes , 2000, J. Comput. Aided Mol. Des..
[18] Peter Riederer,et al. MAO-inhibitors in Parkinson's Disease , 2011, Experimental neurobiology.
[19] Robert J. Doerksen,et al. Docking Challenge: Protein Sampling and Molecular Docking Performance , 2013, J. Chem. Inf. Model..
[20] Julio Caballero,et al. Computational study of the binding orientation and affinity of PPARγ agonists: inclusion of ligand-induced fit by cross-docking , 2016 .
[21] Garland R. Marshall,et al. An Automated Strategy for Binding-Pose Selection and Docking Assessment in Structure-Based Drug Design , 2016, J. Chem. Inf. Model..
[22] I. Waizenegger,et al. A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation , 2016, Molecular Cancer Therapeutics.
[23] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[24] Peng Xie,et al. Identification of a novel family of BRAF(V600E) inhibitors. , 2012, Journal of medicinal chemistry.
[25] R. Friesner,et al. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .
[26] E. Laird,et al. Non-oxime inhibitors of B-Raf(V600E) kinase. , 2011, Bioorganic & medicinal chemistry letters.
[27] Giulio Rastelli,et al. Structure-based design of potent aromatase inhibitors by high-throughput docking. , 2011, Journal of medicinal chemistry.
[28] Kenichi A Tanaka,et al. Blood Coagulation: Hemostasis and Thrombin Regulation , 2009, Anesthesia and analgesia.
[29] Alba Chimirri,et al. Induced‐Fit Docking Approach Provides Insight into the Binding Mode and Mechanism of Action of HIV‐1 Integrase Inhibitors , 2009, ChemMedChem.
[30] Gerhard Klebe,et al. Fragment Binding Can Be Either More Enthalpy-Driven or Entropy-Driven: Crystal Structures and Residual Hydration Patterns Suggest Why. , 2015, Journal of medicinal chemistry.
[31] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[32] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[33] C. Pritchard,et al. Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.
[34] Roberta Menabò,et al. Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. , 2011, Biochimica et biophysica acta.
[35] Andrea Mattevi,et al. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. , 2005, Journal of medicinal chemistry.
[36] Gerhard Klebe,et al. Ligand binding stepwise disrupts water network in thrombin: enthalpic and entropic changes reveal classical hydrophobic effect. , 2012, Journal of medicinal chemistry.
[37] G Klebe,et al. Impact of ligand and protein desolvation on ligand binding to the S1 pocket of thrombin. , 2012, Journal of molecular biology.
[38] Andrea Mattevi,et al. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] D S Goodsell,et al. Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.
[40] James Tsai,et al. RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.
[41] S Alban,et al. Pharmacological strategies for inhibition of thrombin activity. , 2008, Current pharmaceutical design.
[42] Peter Florian,et al. 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor. , 2013, Journal of medicinal chemistry.
[43] Tomoyasu Ishikawa,et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.
[44] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[45] Hieu T. Do,et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. , 2006, Cancer research.
[46] Gerhard Klebe,et al. Fragments Can Bind Either More Enthalpy or Entropy-Driven: Crystal Structures and Residual Hydration Pattern Suggest Why. , 2015 .
[47] Tamás Tábi,et al. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease , 2018, Journal of Neural Transmission.
[48] P Théroux,et al. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.
[49] Yong Zhou,et al. Roll: a new algorithm for the detection of protein pockets and cavities with a rolling probe sphere , 2010, Bioinform..
[50] Woody Sherman,et al. Generation of Receptor Structural Ensembles for Virtual Screening Using Binding Site Shape Analysis and Clustering , 2012, Chemical biology & drug design.
[51] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[52] Andrea Mattevi,et al. Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. , 2008, Journal of medicinal chemistry.
[53] Mark R Player,et al. 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[54] Andrea Mattevi,et al. Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. , 2012, ACS medicinal chemistry letters.
[55] Julio Caballero,et al. Insights into the Interactions between Maleimide Derivates and GSK3β Combining Molecular Docking and QSAR , 2014, PloS one.
[56] Julio Caballero,et al. Is It Reliable to Use Common Molecular Docking Methods for Comparing the Binding Affinities of Enantiomer Pairs for Their Protein Target? , 2016, International journal of molecular sciences.
[57] Alan P Graves,et al. GSK114: A selective inhibitor for elucidating the biological role of TNNI3K. , 2016, Bioorganic & medicinal chemistry letters.
[58] Maryse Lowinski,et al. The use of virtual screening and differential scanning fluorimetry for the rapid identification of fragments active against MEK1. , 2013, Bioorganic & medicinal chemistry letters.
[59] Julio Caballero,et al. Docking and quantitative structure–activity relationship studies for imidazo[1,2-a]pyrazines as inhibitors of checkpoint kinase-1 , 2011, Medicinal Chemistry Research.
[60] David Ramírez. Computational Methods Applied to Rational Drug Design , 2016, The open medicinal chemistry journal.
[61] Julio Caballero,et al. Computational Study on the Interaction of N1 Substituted Pyrazole Derivatives with B-Raf Kinase: An Unusual Water Wire Hydrogen-Bond Network and Novel Interactions at the Entrance of the Active Site , 2010, J. Chem. Inf. Model..
[62] K. Stringer,et al. Hirudins: Antithrombin Anticoagulants , 1992, The Annals of pharmacotherapy.
[63] B. Tomczuk,et al. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. , 2004, Bioorganic & medicinal chemistry letters.
[64] Mathew J Garnett,et al. Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.
[65] Elizabeth Yuriev,et al. Latest developments in molecular docking: 2010–2011 in review , 2013, Journal of molecular recognition : JMR.
[66] Nanxin Li,et al. B-Raf kinase inhibitors for cancer treatment. , 2007, Current opinion in investigational drugs.
[67] G. V. Paolini,et al. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..
[68] Angelo Carotti,et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. , 2007, Journal of medicinal chemistry.
[69] Mirko Zimic,et al. Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors , 2011, J. Comput. Aided Mol. Des..
[70] Michal Vieth,et al. Lessons in Molecular Recognition, 2. Assessing and Improving Cross-Docking Accuracy , 2007, J. Chem. Inf. Model..
[71] Andrea Mattevi,et al. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. , 2004, Journal of medicinal chemistry.